2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess if the combination of erlotinib and chemotherapy
(docetaxel in case of squamous cell NSCLC or pemetrexed in case of other histological types)
is superior to erlotinib alone and has acceptable tolerability and safety in the 2nd line
treatment of patients with advanced/metastatic non-small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Dutch Society of Physicians for Pulmonology and Tuberculosis